Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.

[powerpress]

Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.

[powerpress]

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.

[powerpress]